FORM PTO-1449 (Modified [illegible])

ATTY. DOCKET NO.	SERIAL NO.
13761-739	09/715,764

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT(S)' INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

INVENTOR	
Lenz, Heinz-Josef, et al.	
FILING DATE	GROUP ART UNIT
11/15/2000	~~1645~~ 1655

REFERENCE DESIGNATION **U.S. PATENT DOCUMENTS**

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	NAME	Class	Subclass	Filing Date If Appropriate
	A1						
	A2						
	A3						

FOREIGN PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	Subclass	TRANSLAT'N yes	TRANSLAT'N no
	B1							
	B2							
	B3							
	B4							
	B5							

OTHER ART (Include Author, Title, Date, Pertinent Pages, *etc.*)

SF	C1	Caporaso, N. Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens. *Ann. 1st Super Sanita.* **27**:621-30 (1991).
	C2	Chomczynski, P and Sacchi, N. Single-step method of RNA isolation by acid guanidinium. thiocyanate-phenol-chloroform extraction. *Anal. Biochem* **162:**156-159 (1987).
	C3	Curt, G.A. *et al;* Unstable methtrexate resistance in human small cell carcinomas associated with double minute chromosomes. *N Engl J Med* **308:**199-202 (1983).
	C4	Danenberg, P. Thymidylate Synthetase - A target enzyme in cancer chemotherapy. *Biochemica et Biophysica Acta* **473:**73-92 (1977).
	C5	Heidelberger, C; Chandari, N.K; Danenberg, P.*et al.* Fluorinated pyrimidines: A new class of tumor inhibitory compounds. *Nature* **179:**663-666 (1957).
	C6	Horie, N; Aiba,H; Ogura,K; Hojo, H; and Takeishi, K; Functional Analysis and DNA polymorphism of the tandemly repeated sequences in the 5' -terminal regulatory region of the human gene for thymidylate synthase. *Cell Structure and function* **20:**191-197 (1995).
	C7	Horie, N; Chimoto,M; Nozawa,R; and Takeishi,K; Characterization of the regulatory sequences and nuclear factors that function in cooperation with the promoter of the human thymidylate synthase gene. *Biochim. Biophys. Acta* **1216:**409-416.
	C8	Horikoshi, T. *et al.* Quantitation of thymidylate synthase ,dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. *Cancer Research* **52:**108-116 (1992).

EXAMINER S. Kromer	DATE CONSIDERED 6-29-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance *and* not considered. Include copy of this form with next communication to Applicant(s).

FORM PTO-1449 (Modified [redacted])

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT(S)' INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
13761-739	09/715,764
INVENTOR: Lenz, Heinz-Josef, et al.	
FILING DATE: 11/15/2000	GROUP ART UNIT: 1645

	C9	Ikawa, S. et al. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. *Pharmacogenetics* **5**:S154-60 (1995).
	C10	Iyer, L. and Ratain, M.J. Pharmacogenetics and cancer chemotherapy. *Eur. J. Cancer* **34**:1493-9 (1998).
	C11	Leichman, C.G. *et al.* Quantitation of Intratumoral Thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. *Journal of Clinical Oncology* **15:**3223-3229 (1997).
	C12	Lenz, H.J. *et al.* Thymidylate Synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. *Journal of Clinical Oncology* **14:**176-182 (1995).
	C13	Marsh, S. *et al* Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. *Genomics* **58:**310-312 (1999).
	C14	Moertel, C.G. Chemotherapy for colorectal cancer. *N.Engl.J.Med* **330:**1136-1142 (1994).
	C15	Nebert, D.W. et al. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. *DNA Cell Biol.* **15**:273-80 (1996).
	C16	Ng, S.Y.et al. Evolution of the functional β actin gene and its multipseudogene family: Conservation of non-coding regions and chromosomal dispersion of pseudogenes. *Mol Cell Biol* **5:**2720-2732.(1985).
	C17	Santi, D.V; Mc Henry, C.S; Sommer,H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. *Biochemistry* **13:**471-481 (1974).
	C18	Shields, P.G. et al. Pharmacogenetics: detecting sensitive populations. *Environ Health Perspect.* **102 Suppl 11**:81-7 (1994). On-line version pp. 1-13.
	C19	Takeishi, K.et al. Nucleotide sequence of a functional cDNA for thymidylate synthase.*Nucleic Acids Res* **13:**2035-2045 (1985).
✓	C20	Zar, J.H. *Biostatical Analysis.* Prentice-Hall, Inc, Englewood Cliffs, N.J., Chapter 12, 151-162.(1974).

EXAMINER S. Ziska	DATE CONSIDERED 6-29-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance *and* not considered. Include copy of this form with next communication to Applicant(s).